Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced the completion of its public offering of 5,175,000 shares of common stock at $31.00 per share, raising approximately $160.4 million in gross proceeds. This offering included 675,000 shares from the underwriters' option to purchase additional shares. The offering was managed by J.P. Morgan, Piper Sandler, and Stifel, with RBC Capital Markets and Needham & Company also involved. Proceeds are expected to support the company's drug development efforts targeting E3 ligases for cancer treatment.
- Gross proceeds of approximately $160.4 million to support drug development.
- Successful completion of public offering indicates strong investor interest.
- Dilution risk for existing shareholders due to the increase in shares outstanding.
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of
J.P. Morgan, Piper Sandler and Stifel acted as the joint bookrunning managers for the offering. RBC Capital Markets and Needham & Company acted as the lead managers for the offering.
The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or via email at prospectus@psc.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or via email at syndprospectus@stifel.com.
A registration statement relating to the sale of these securities was declared effective by the Securities and Exchange Commission (SEC) on March 4, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation.
Cautionary Statement Regarding Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nurix Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that may cause Nurix’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including, without limitation, risks and uncertainties related to market conditions and the risks and uncertainties described under the heading “Risk Factors” in documents Nurix files from time to time with the SEC, including Nurix’s Annual Report on Form 10-K filed with the SEC on February 16, 2021, the prospectus for this offering filed with the SEC on March 5, 2021, and its future periodic reports to be filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date of this press release, and Nurix undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contact
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
jkantor@nurixtx.com
Media Contact
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
FAQ
What was the public offering price of NRIX shares?
How many shares were offered by Nurix Therapeutics?
What are the intended uses of the proceeds from NRIX's offering?
Who managed the public offering for Nurix Therapeutics?
When was the registration statement for NRIX's offering declared effective?
